110368-33-7

Basic information

• Product Name: CH 55
• Synonyms: CH 55;4-[(1E)-3-[3,5-BIS(1,1-DIMETHYLETHYL)PHENYL]-3-OXO-1-PROPENYL]BENZOIC ACID;4-[(E)-3-(3,5-Di-tert-butylphenyl)-3-oxo-1-propenyl]benzoic acid;4-[(E)-3-[3,5-Bis(1,1-dimethylethyl)phenyl]-3-oxo-1-propenyl]benzoic acid;4-[(E)-3-[3,5-Bis(tert-butyl)phenyl]-3-oxo-1-propenyl]benzoic acid;(E)-4-(3-(3,5-Bis(1,1-dimethylethyl)phenyl)-3-oxo-1-propenyl)benzoic acid;Benzoic acid, 4-(3-(3,5-bis(1,1-dimethylethyl)phenyl)-3-oxo-1-propenyl)-, (E)-
• CAS NO: 110368-33-7
• Molecular Formula: C₂₄H₂₈O₃
• Molecular Weight: 364.48
• Product Categories: Intracellular receptor
• Mol File: 110368-33-7.mol

Chemical Properties

• Melting Point: 202-203.5 °C
• Boiling Point: 509.5°Cat760mmHg
• Flash Point: 276°C
• Appearance: /
• Density: 1.085g/cm³
• Vapor Pressure: 3.33E-11mmHg at 25°C
• Refractive Index: 1.574
• Storage Temp.: Store at RT
• PKA: 4.09±0.10(Predicted)
• CAS DataBase Reference: CH 55(CAS DataBase Reference)
• NIST Chemistry Reference: CH 55(110368-33-7)
• EPA Substance Registry System: CH 55(110368-33-7)

Safety Data

• Hazardous Substances Data: 110368-33-7(Hazardous Substances Data)

Usage

Uses

Used in Cancer Chemoprevention and Therapy:
CH 55 is used as a promising agent for cancer chemoprevention and therapy. Its ability to inhibit angiogenesis makes it a potential candidate for preventing the development and progression of various types of cancer.
Used in Angiogenesis Inhibition:
CH 55 is used as an effective inhibitor of angiogenesis for preventing the formation of new blood vessels that supply nutrients and oxygen to cancer cells, thereby limiting their growth and spread.

Biological Activity

Highly potent synthetic retinoid that has high affinity for RAR- α and RAR- β receptors and low affinity for cellular retinoic acid binding protein (CRABP). Inhibits rabbit tracheal epithelial cell differentiation by inhibiting transglutaminase and increasing cholesterol sulfate (EC 50 values are 0.02 and 0.03 nM respectively). Induces differentiation of embryonic carcinoma F9 and melanoma S91 cells (EC 50 values are 0.26 and 0.5 nM respectively) and inhibits the induction of ornithine decarboxylase activity in 3T6 fibroblasts (EC 50 = 1 nM).

InChI:InChI=1/C24H28O3/c1-23(2,3)19-13-18(14-20(15-19)24(4,5)6)21(25)12-9-16-7-10-17(11-8-16)22(26)27/h7-15H,1-6H3,(H,26,27)/b12-9+

Upstream product

• 1756-31-6 1-(3,5-di-tert-butylphenyl)ethanone 
• 1571-08-0 methyl 4-formylbenzoate 

Relevant articles and documents

Method of treating bone disease with pyridine, carboxamide and carboxylic derivatives

Treatment of osteopathic comprising administering as an active ingredient a compound represented by the following formula (I), (II) or (III): STR1

Retinobenzoic Acids. Structure-Activity Relationships of Chalcone-4-carboxylic Acids and Flavone-4'-carboxylic Acids

The structure-activity relationships of (E)-chalcone-4-carboxylic acids, which are retinoidal benzoic acids represented by R-Ph-X-Ph-COOH (4, X=-COCH=CH-), are discussed on the basis of differentiation-inducing activity on human promyelocytic leukemia cells HL-60.The activity was increased by the substitution of a bulky alkyl group(s) (R), and among such compounds, (E)-4-benzoic acid (Ch55) and (E)-4-benzoic acid (Ch80) are several times more active than retinoic acid.Though the stable conformer of chalcone derivatives is linear (s-cis form), the conformationally restricted analogue 4-(6,7,8,9-tetrahydro-6,6,9,9-tetramethyl-4H-4-oxonaphthopyran-2-yl)benzoic acid (Fv80) is more active than Ch80.While the effect of introduction of an oxygen atom varied, 4-benzoic acid (Re80), regarded as a derivative of Ch80 with two additional hydroxyl groups, has very strong activity.